- Report
- February 2024
- 250 Pages
Global
From €4793EUR$5,000USD£4,005GBP
From €3355EUR$3,500USD£2,804GBP
- Report
- August 2022
- 119 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- November 2023
- 276 Pages
Global
From €9107EUR$9,500USD£7,610GBP
- Report
- April 2023
- 120 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1438EUR$1,500USD£1,202GBP
- Report
- April 2025
- 50 Pages
Global
From €2540EUR$2,650USD£2,123GBP
Lapatinib is a targeted therapy drug used to treat certain types of lung cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. It is typically used in combination with other chemotherapy drugs to treat non-small cell lung cancer (NSCLC). Lapatinib is also used to treat advanced or metastatic breast cancer.
Lapatinib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2007. It is used to treat patients with advanced NSCLC who have already been treated with other chemotherapy drugs. It is also used to treat patients with advanced or metastatic breast cancer who have already been treated with other chemotherapy drugs.
The Lapatinib market is highly competitive, with several companies offering the drug. Some of the major players in the market include GlaxoSmithKline, Novartis, Pfizer, and AstraZeneca. Show Less Read more
